Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elia Aguado-Fraile
Observed names:
E. Aguado-Fraile,
Elia Aguado,
Elia Aguado-fraile
Observed institutions:
Tufts University,
Tufts Medical Center,
Agios Pharmaceuticals (United States),
Relay Therapeutics (United States),
Instituto Ramón y Cajal de Investigación Sanitaria,
Hospital Universitario Ramón y Cajal
show all 6
ORCID:
0009-0007-3130-3927
Observed ORCID:
0009-0007-3130-3927
OpenAlex ID:
A5017898191
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
2021
·
Andrew X. Zhu
, Teresa Macarulla
, et al.
·
JAMA Oncology
·
514
PDF
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
2021
·
Peter Kalev
, Marc L. Hyer
, et al.
·
Cancer Cell
·
247
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
2019
·
Maeve A Lowery
, Howard A Burris
, et al.
·
The Lancet. Gastroenterology & hepatology
·
224
Hypoxia Inducible Factor 1-Alpha (HIF-1 Alpha) Is Induced during Reperfusion after Renal Ischemia and Is Critical for Proximal Tubule Cell Survival
2012
·
Elisa Conde
, Laura Alegre
, et al.
·
PLoS ONE
·
164
PDF
A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury
2015
·
Elia Aguado-Fraile
, Edurne Ramos
, et al.
·
PLoS ONE
·
129
PDF
miR-127 Protects Proximal Tubule Cells against Ischemia/Reperfusion: Identification of Kinesin Family Member 3B as miR-127 Target
2012
·
Elia Aguado-Fraile
, Edurne Ramos
, et al.
·
PLoS ONE
·
70
PDF
Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis
2012
·
Leticia Muñoz
, María José Borrero
, et al.
·
Hepatology
·
63
HIF-1α induction during reperfusion avoids maladaptive repair after renal ischemia/reperfusion involving miR127-3p
2017
·
Elisa Conde
, Sara Giménez-Moyano
, et al.
·
Scientific Reports
·
55
PDF
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
2025
·
Mrinal Gounder
, Melissa Johnson
, et al.
·
Nature Communications
·
53
PDF
MicroRNAs in the kidney: novel biomarkers of acute kidney injury.
2013
·
Elia Aguado-Fraile
, Edurne Ramos
, et al.
·
PubMed
·
48
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
2025
·
Haineng Xu
, Erin George
, et al.
·
Nature Communications
·
33
PDF
Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma
2021
·
Elia Aguado-Fraile
, Ania Tassinari
, et al.
·
Future Oncology
·
28
IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.
2020
·
Elia Aguado
, Ghassan K. Abou-Alfa
, et al.
·
Journal of Clinical Oncology
·
26
Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
2023
·
Timothy A Yap
, Alison Schram
, et al.
·
Molecular Cancer Therapeutics
·
21
Exth-59. the Idh1 Mutant Inhibitor Ag-120 Shows Strong Inhibition of 2-hg Production in an Orthotopic Idh1 Mutant Glioma Model in Vivo
2017
·
Brandon Nicolay
, Rohini Narayanaswamy
, et al.
·
Neuro-Oncology
·
18
PDF
Differential resolution of inflammation and recovery after renal ischemia–reperfusion injury in Brown Norway compared with Sprague Dawley rats
2010
·
David Sáenz-Morales
, Elisa Conde
, et al.
·
Kidney International
·
18
Exth-34. Combined Use of the Pan-idh Mutant Inhibitor Ag-881 With Radiation Therapy Shows Added Benefit in an Orthotopic Idh1 Mutant Glioma Model in Vivo
2017
·
Brandon Nicolay
, Rohini Narayanaswamy
, et al.
·
Neuro-Oncology
·
12
PDF
Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)
2025
·
Alison M. Schram
, Elizabeth K. Lee
, et al.
·
Cancer Research
·
10
The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines
2019
·
Oksana B. Serebrennikova
, Maria D. Paraskevopoulou
, et al.
·
Proceedings of the National Academy of Sciences
·
9
Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
2019
·
Rebecca S Heist
, Mrinal M Gounder
, et al.
·
Molecular Cancer Therapeutics
·
8
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
2025
·
Jinkai Wan
, Hatice Duygu Saatcioglu
, et al.
·
Clinical Cancer Research
·
6
504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)
2024
·
Z.A. Wainberg
, A.H. Bent
, et al.
·
Annals of Oncology
·
5
PDF
Abstract C163: KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition
2023
·
Marc L. Hyer
, Jimmy Fourtounis
, et al.
·
Molecular Cancer Therapeutics
·
5
Abstract 5650: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells
2022
·
Jimmy Fourtounis
, John Martino
, et al.
·
Cancer Research
·
3
Abstract 3090: The MAT2A inhibitor, AG-270, combines with both taxanes and gemcitabine to yield enhanced anti-tumor activity in patient-derived xenograft models
2020
·
Marc L. Hyer
, Peter Kalev
, et al.
·
Cancer Research
·
3
Show more works
View as search
Works count:
48
Citation count:
1,784
H-index:
16
I10-index:
18
Year
Topic
Type
